From Apollo™X Cell Line To 20K L Bioreactor: Partnering Manufacturing Strategies And Facility Design For Patient-Centric Medicine Delivery

Manufacturing therapeutic recombinant proteins from mammalian cell culture presents unique challenges. Traditional strategies like scale-up, scale-out, and continuous manufacturing are suited for different supply scenarios, but transitioning between them often requires significant investment and time.

Our KojoX™ platform offers a modular approach to manufacturing, addressing these challenges, and ensuring a robust supply chain for medicines. By standardizing process design, validation, and operation, KojoX™ de-risks the production process, from pre-clinical to commercial scale.

Key Learning Objectives:

• Navigating Supply Chain Challenges: Understand the impact of global supply chain disruptions and rising costs on biologics manufacturing.
• Optimizing Production Strategies: Evaluate different production strategies to meet the evolving demands of the market for rapid and cost-effective therapy delivery.
• Accelerating Time to Market: Learn how standardized, modular process designs can reduce risks and enhance scalability, from early-stage development to large-scale manufacturing.

This presentation delves into the importance of selecting the most suitable manufacturing strategy and how KojoX™, combined with our Apollo™X technology, can streamline the process from cell line development to commercial production at 20K L scale.